Cellular Adaptations to Training in Patients With Type 2 Diabetes (TrainAiD)

Physical training can improve metabolic health in patients with insulin resistance and/or type 2 diabetes (T2D). The cellular and molecular changes underlying the improvements in metabolic health are multi-factorial and only partly understood, but most likely involve adaptation at a multi-organ level that includes improvements in skeletal muscle glucose uptake and adipose tissue insulin sensitivity.

The aim of this project is to study the transcriptional differences in skeletal muscle and adipose tissue at baseline and after a 3-month physical training program in obese patients with and without T2D and to use this information to identify novel therapeutic targets for improvement of glucose disposal and insulin sensitivity in patients with T2D.

Thus, the investigators aim to find answers to the question: What is the mechanism behind the effect of physical activity on insulin sensitivity in type 2 diabetes?

Study Overview

• Status: Recruiting
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Behavioral: Aerobic exercise training

Detailed Description

Background and aim

Physical training can improve metabolic health in patients with insulin resistance and/or type 2 diabetes (T2D). The cellular and molecular changes underlying the improvements in metabolic health are multi-factorial and only partly understood, but most likely involve adaptation at a multi-organ level that includes improvements in skeletal muscle glucose uptake and adipose tissue insulin sensitivity.

The literature on the effects of an acute bout of exercise on glucose uptake in skeletal muscle is large, but so far, there is a lack of studies investigating the specific molecular basis for the insulin sensitizing effect of regular physical training.

The aim of this project is to study the transcriptional differences in skeletal muscle and adipose tissue at baseline and after a 3-month physical training program in obese patients with and without T2D and to use this information to identify novel therapeutic targets for improvement of glucose disposal and insulin sensitivity in patients with T2D.

Thus, the investigators aim to find answers to the question: What is the mechanism behind the effect of physical activity on insulin sensitivity in type 2 diabetes?

Methods

Thirty obese patients with (n=15) and without (n=15) type 2 diabetes will be included in the study.

Design: Cohort Study Intervention: 12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2max is measured to ensure sufficient adjustment of the workload during the training sessions.

Experimental methods: Before (1-2 weeks) and after the intervention, the following tests and measurements are performed:

Day A: (Overnight fasting. Duration approx. 3 h)

• Dual energy x-ray absorptiometry (DXA) scan (body composition and body fat)
• Graded exercise test on an ergometer bike (maximal fat oxidation rate)
• Maximal oxygen consumption test (VO2max)
• Handgrip strength (by dynamometer)
• Leg power (Power Rig and sit-to-stand test)

Day B: (Overnight fasting. Duration approx. 9 h)

• 2-step euglycemic, hyperinsulinemic clamp
• Muscle biopsy vastus lateralis
• Fat biopsy subcutaneous lower abdomen
• Flow measurements (Femoral artery by Doppler ultrasound and forearm by strain-gauge plethysmography)
• Energy expenditure (ventilated hood method)

Day A and B are repeated after the training intervention has finished.

Analytical methods:

1. Muscle and fat biopsies: Mitochondrial respiratory capacity and reactive oxygen species production. Single nuclei RNA sequencing (snSeq). Fiber type determination and capillarization.
2. Blood samples: Hormones, metabolites and substrates (e.g. insulin, catecholamines, cortisol, glucose, lactate, pyruvate, ketone bodies, cytokines, and myokines). Plasma proteomic/peptidomic analysis.

In summary, this study will reveal cell types and genes in skeletal muscle and adipose tissue that are affected by training and/or that shows differential regulation in patients with T2D versus control subjects.

Statistical considerations:

A power calculation indicates that a significant difference in training induced insulin sensitivity will be detectable when n ≥ 10, based on power = 0.95 and level of significance set to P<0.05. This allows for a dropout rate of a 15-20% with some margin. Mixed model analysis will be used for data analysis of phenotypical data, and bioinformatical tools for the snSeq data and for the interaction between gene- and phenotype expression.

Ethical considerations:

The project was approved by The Regional Ethical Committee of the Capital Region (H-20046605) the 15th of December 2020.

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Maria Hansen, MD; Phone Number: +4529210442; Email: mariahan@sund.ku.dk

Study Locations

• Denmark
  • Copenhagen, Denmark, 2200
    • Recruiting
    • Xlab, Faculty of Health and Medical Sciences, University of Copenhagen
    • Contact: Flemming Dela, MD, DMSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 60 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Overweight to obese (BMI 28-35 kg/m2)
• Normal resting ECG

Specific for patients with T2D:

• In antiglycemic treatment with diet +/- metformin, SLGT-2 inhibitors, sulfonylurea, GLP1-RA, or DPPV-4 inhibitors
• Time since diagnosis max 4 yrs

Exclusion Criteria:

• Diagnosed with cardiovascular disease (minor to moderate hypertension allowed, defined as prescribed maximally two different antihypertensive drugs)
• Epilepsy
• Kidney disease (GFR<50 ml/min)
• Regular exercise activity
• Inability to perform bicycling and rowing ergometer exercise
• Inability to understand Danish language (written and spoken)

Specific for patients with T2D:

- Insulin treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Diabetes; Aerobic exercise training	Behavioral: Aerobic exercise training; 12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
EXPERIMENTAL: Healthy; Aerobic exercise training	Behavioral: Aerobic exercise training; 12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Insulin sensitivity	Euglycemic hyperinsulinemic clamp	Change from baseline at 12 weeks
Blood flow	Pulsed-wave Doppler ultrasound (A. femoralis) and venous occlusion strain-gauge plethysmography (forearm)	Change from baseline at 12 weeks
Gene expression will be quantitatively determined at cellular resolution using single nuclei sequencing	The snSeq data will be analysed using state of the art computational approaches to detect changes in cell type composition and differences in gene expression patterns of specific cell types. These approaches will include: I) normalizations of raw counts; II) feature selection based on most variable genes; III) Conos or Canonical correlation analysis to align the cells across samples; IV) Visualization using dimensionality reduction approaches such as Uniform Approximation and Projection (UMAP) and t-distributed Stochastic Neighbour Embedding (t-SNE); V) RNA velocity and trajectory inference methods to follow changes in cell type identities.	Change from baseline at 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glucose homeostasis	Changes in HbA1c concentration	Change from baseline at 12 weeks
Cardiorespiratory fitness	Changes in maximal oxygen uptake	Baseline and after 3, 6, 9 and 12 weeks of aerobic exercise training

Collaborators and Investigators

• Sponsor: University of Copenhagen
• Collaborators: Novo Nordisk A/S
• Investigators: Principal Investigator: Flemming Dela, MD, DMSc, University of Copenhagen

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 20, 2021
• Primary Completion (ANTICIPATED): July 1, 2022
• Study Completion (ANTICIPATED): October 1, 2023

Study Registration Dates

• First Submitted: June 7, 2021
• First Submitted That Met QC Criteria: June 29, 2021
• First Posted (ACTUAL): June 30, 2021

Study Record Updates

• Last Update Posted (ACTUAL): June 30, 2021
• Last Update Submitted That Met QC Criteria: June 29, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Keywords: Aerobic exercise; Diabetes Mellitus, Type 2; Insulin sensitivity
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: Training Adaptations in T2D

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Can be provided upon reasonable request

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No